UNSPSC 51292903: Depramine

This classification denotes an antidepressant agent with the molecular formula C19H22N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 77C3T28736, chemically known as 10,11-dehydroimipramine but generally known as depramine, which bears US NIH Compound Identifier 67534. European Medicines Agency schedules Depramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06981MIG.

UNSPSC 51292903 Depramine is a Commodity code that captures state and local government procurement of pharmaceutical products, including naloxone, generic multi-source drugs, and over-the-counter medications distributed through authorized wholesale channels and community health programs. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances that consolidate procurement across multiple jurisdictions. The work ranges from direct purchase of emergency medical supplies like naloxone for community health initiatives to large-scale cooperative contracting for generic pharmaceuticals and OTC products supplied through authorized wholesalers with established chargeback and inventory systems. Vendors typically must comply with FDA manufacturing standards, Drug Supply Chain Security Act requirements, Good Manufacturing Practices certification, and federal compliance obligations when contracts include FEMA or state funding. Contracts generally require substantial insurance coverage, E-Verify employment verification, and fixed-fee or net-price pricing models.

Recent activity spans Florida, Texas, and Minnesota through diverse procurement mechanisms. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, signaling state movement toward alternative contracting models outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson, with proposals due March 26, 2026. The MMCAP contract emphasizes price competitiveness (75 percent evaluation weight), mandatory relationships with at least two authorized wholesalers, and serves participating state and local facilities including Oregon.